• Tumors including breast, prostate, lung, and oral cancer can establish in bone and disrupt normal bone remodeling.
• Our group and others have shown that Gli2, a Hedgehog signaling transcription factor regulates parathyroid hormone related protein expression and bone destruction.
• Genetic inhibition of Gli2 dramatically reduces tumor induced bone disease.
• Hedgehog inhibitors have not been successful in most tumor in bone, since they often do not express Hedgehog receptors.
• The available Gli inhibitors (including GANT58) are hydrophobic and challenging to deliver in vivo.
MATERIALS & METHODS BACKGROUND HYPOTHESIS RESULTS
• Microparticles: GANT58 microparticles (GANT58-MPs) were fabricated using an oil-in-water single emulsion technique. GANT58-MPs averaged 4.2 μm in diameter and exhibited ROS-dependent release characteristics in vitro.
• Nanoparticles: The GANT58 nanoparticles (GANT58-NPs) were made using an oil-in-water solvent evaporation method. Reactive oxygen species (ROS) trigger particle disassembly and drug release.
Encapsulation of Gli inhibitors will facilitate delivery of these agents to tumors in bone will help reduce tumor induced bone disease. 
VA N D E R B I LT C E N T E R F O R B O N E B I O L O G Y

CONCLUSIONS
FUNDING NANOPARTICLE SYSTEMIC DELIVERY OF GANT58
MICROPARTICLE LOCAL DELIVERY OF GANT58 Experimental Design: 1x10 6 cells were injected into the right and left masseter muscle (parallel to the mandible) of 4-6 week old athymic male mice from Harlan Laboratories. Tumor control mice received PBS injections. Drug treatments began once tumors were palpable (~10 days) which consisted of 50-75 µl injections of~5mg/kg GANT58 loaded microparticles or empty-PPS microparticles as controls. 
